Cited by 420Computational Drug Discovery MethodsCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record, with a small difference in title or year; 10 of the 10 references it cites were found in a registry or an index.

Pharmacogenomic agreement between two cancer cell line data sets

Open access

The Cancer Cell Line Encyclopedia Consortium, The Genomics of Drug Sensitivity in Cancer Consortium·2015·Nature

DOI 10.1038/nature15736PMC PMC6343827

Open this paper in CoChat — free account

Abstract

Large cancer cell line collections broadly capture the genomic diversity of human cancers and provide valuable insight into anti-cancer drug response. Here we show substantial agreement and biological consilience between drug sensitivity measurements and their associated genomic predictors from two publicly available large-scale pharmacogenomics resources: The Cancer Cell Line Encyclopedia and the Genomics of Drug Sensitivity in Cancer databases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature15736

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citation
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2820 · Cited by 600
Inconsistency in large pharmacogenomic studies
Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013) · Nature · doi:10.1038/nature12831 · Cited by 499
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
Sos, M. L., Michel, K., Zander, T., Weiss, J. M., Frommolt, P., Peifer, M., Li, D., Ullrich, R. T., Koker, M., Fischer, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37127 · Cited by 258
Advances in the preclinical testing of cancer therapeutic hypotheses
Caponigro, G., & Sellers, W. R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3385 · Cited by 165
Comparison and validation of genomic predictors for anticancer drug sensitivity
Papillon‐Cavanagh, S., Jay, N. D., El-Hachem, N., Olsen, C., Bontempi, G., Aerts, H. J. W. L., Quackenbush, J. F., & Haibe‐Kains, B. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001442 · Cited by 65

Flagged first, then by citations

Show all 10 references

Sorted by citations

Items 101–200 of 420

Emerging Opportunities for Target Discovery in Rare Cancers
Sharifnia, T., Hong, A. L., Painter, C., & Boehm, J. S. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.002 · Cited by 51
Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions
Lord, C. J., Quinn, N., & Ryan, C. J. (2020) · eLife · doi:10.7554/elife.58925 · Cited by 46
Choosing wisely – Preclinical test models in the era of precision medicine
Klinghammer, K. F., Walther, W., & Hoffmann, J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.009 · Cited by 50
Unraveling the Prenylation–Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors
Lacbay, C. M., Waller, D. D., Park, J., Palou, M. G., Vincent, F., Huang, X. F., Ta, V., Berghuis, A. M., Sébag, M., & Tsantrizos, Y. S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00886 · Cited by 47
Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers
Price, C. O., Gill, S., Ho, Z. V., Davidson, S. M., Merkel, E., McFarland, J. M., Leung, L., Tang, A., Kost‐Alimova, M., Tsherniak, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2674 · Cited by 47
CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients
Peng, H., Lŭ, L., Zhou, Z., Liu, J., Zhang, D., Nan, K., Zhao, X., Li, F., Tian, L., Hua, D., et al. (2019) · Genes · doi:10.3390/genes10110926 · Cited by 49
Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer
Klein, L., Tu, M., Krebs, N., Urbach, L., Grimm, D. T., Latif, M. U., Penz, F., Blandau, A., Wu, X., Samuel, R. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55330-7 · Cited by 51
Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non–small cell lung cancer
Shi, R., Yu, X., Wang, Y., Sun, J., Sun, Q., Xia, W., Dong, G., Wang, A., Gao, Z., Jiang, F., et al. (2017) · Tumor Biology · doi:10.1177/1010428317695928 · Cited by 46
Systematic illumination of druggable genes in cancer genomes
Jiang, J., Yuan, J., Hu, Z., Zhang, Y., Zhang, T., Xu, M., Long, M., Fan, Y., Tanyi, J. L., Montone, K. T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110400 · Cited by 47
False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal
Drexler, H. G., Dirks, W. G., MacLeod, R. A. F., & Uphoff, C. C. (2017) · International Journal of Cancer · doi:10.1002/ijc.30530 · Cited by 45
Deep learning and multi-omics approach to predict drug responses in cancer
Wang, C., Lye, X., Kaalia, R., Kumar, P., & Rajapakse, J. C. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04964-9 · Cited by 48
Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics
Hafner, M. A., Heiser, L. M., Williams, E. H., Niepel, M., Wang, N. J., Korkola, J. E., Gray, J. W., & Sorger, P. K. (2017) · Scientific Data · doi:10.1038/sdata.2017.166 · Cited by 41
Network control principles for identifying personalized driver genes in cancer
Guo, W.-F., Zhang, S.-W., Zeng, T., Akutsu, T., & Chen, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz089 · Cited by 44
Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells
Niepel, M., Hafner, M. A., Chung, M., & Sorger, P. K. (2017) · Current Protocols in Chemical Biology · doi:10.1002/cpch.21 · Cited by 42
Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer
Hu, D., Ansari, D., Zhou, Q., Sasor, A., Hilmersson, K. S., & Andersson, R. E. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1574360 · Cited by 42
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
Geeleher, P., Cox, N. J., & Huang, R. S. (2016) · Genome biology · doi:10.1186/s13059-016-1050-9 · Cited by 44
Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation
Aldonza, M. B. D., Hong, J., & Lee, S. K. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.131 · Cited by 42
Application of transfer learning for cancer drug sensitivity prediction
Dhruba, S. R., Rahman, R., Matlock, K., Ghosh, S., & Pal, R. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2465-y · Cited by 39
Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y. G., Teicher, B. A., & Krushkal, J. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01026-4 · Cited by 41
A comprehensive evaluation of regression-based drug responsiveness prediction models, using cell viability inhibitory concentrations (IC50 values)
Park, A., Joo, M., Kim, K., Son, W., Lim, G., Lee, J., Kim, J. H., Lee, D. H., & Nam, S. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac177 · Cited by 46
BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene
Yamamoto, T., Hirosue, A., Nakamoto, M., Yoshida, R., Sakata, J., Matsuoka, Y., Kawahara, K., Nagao, Y., Nagata, M., Takahashi, N., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0907-6 · Cited by 38
The Network of Cancer Genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screensPreprint
Repana, D., Nulsen, J., Dreßler, L., Bortolomeazzi, M., Venkata, S. K., Tourna, A., Yakovleva, A., Palmieri, T., & Ciccarelli, F. D. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/389858 · Cited by 38
Ranking Breast Cancer Drugs and Biomarkers Identification Using Machine Learning and Pharmacogenomics
Mehmood, A., Nawab, S., Jin, Y., Hassan, H., Kaushik, A. C., & Wei, D. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00212 · Cited by 38
Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses
Fujita, N., Mizuarai, S., Murakami, K., & Nakai, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-28066-w · Cited by 37
More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens
Ling, A. L., Gruener, R. F., Fessler, J. L., & Huang, R. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.014 · Cited by 35
Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy
El-Hachem, N., Gendoo, D. M. A., Ghoraie, L. S., Safikhani, Z., Smirnov, P., Chung, C., Deng, K., Fang, A., Birkwood, E., Ho, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0096 · Cited by 36
Assessment of Genetic Drift in Large Pharmacogenomic Studies
Quevedo, R., Smirnov, P., Tkachuk, D., Ho, C., El-Hachem, N., Safikhani, Z., Pugh, T. J., & Haibe‐Kains, B. (2020) · Cell Systems · doi:10.1016/j.cels.2020.08.012 · Cited by 43
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma
Sethi, N. S., Kikuchi, O., McFarland, J. M., Zhang, Y., Chung, M., Kafker, N., Islam, M., Lampson, B. L., Chakraborty, A. A., Kaelin, W. G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128439 · Cited by 35
Assessment of pharmacogenomic agreement
Safikhani, Z., El-Hachem, N., Quevedo, R., Smirnov, P., Goldenberg, A., Birkbak, N. J., Mason, C. E., Hatzis, C., Shi, L. M., Aerts, H. J. W. L., et al. (2016) · F1000Research · doi:10.12688/f1000research.8705.1 · Cited by 31
O-GlcNAc Transferase – An Auxiliary Factor or a Full-blown Oncogene?
Itkonen, H. M., Loda, M. F., & Mills, I. G. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0926 · Cited by 32
Inhibiting cancer metabolism by aromatic carbohydrate amphiphiles that act as antagonists of the glucose transporter GLUT1
Brito, A., Pereira, P. M. R., da Costa, D. S., Reis, R. L., Ulijn, R. V., Lewis, J. S., Pires, R. A., & Pashkuleva, I. (2020) · Chemical Science · doi:10.1039/d0sc00954g · Cited by 33
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency datasetsPreprint
Dempster, J. M., Pacini, C., Pantel, S., Behan, F. M., Green, T., Krill-Burger, J. M., Beaver, C., Younger, S. T., Zhivich, V., Najgebauer, H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/604447 · Cited by 32
In Vitro and In Silico Mechanistic Insights into miR-21-5p-Mediated Topoisomerase Drug Resistance in Human Colorectal Cancer Cells
Chen, J., Hsieh, Y., Lo, H.-L., Li, A., Chou, C.-J., & Yang, P. (2019) · Biomolecules · doi:10.3390/biom9090467 · Cited by 31
Computational estimation of quality and clinical relevance of cancer cell lines
Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31
Self-citation
Pooled genetic screens with image‐based profiling
Walton, R. T., Singh, A. K., & Blainey, P. C. (2022) · Molecular Systems Biology · doi:10.15252/msb.202110768 · Cited by 29
Ribosomal protein S11 influences glioma response to TOP2 poisons
Awah, C. U., Chen, L., Bansal, M., Mahajan, A., Winter, J., Lad, M., Warnke, L., González-Buendía, E., Park, C., Zhang, D. Y., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1342-0 · Cited by 30
An integrated pan‐cancer analysis of TFAP4 aberrations and the potential clinical implications for cancer immunity
Liu, J., Kong, X., Ping, S., Wang, R., Li, W., & Chen, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16147 · Cited by 29
Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression
Li, W., & Zhao, Y. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_32_18 · Cited by 29
Colorectal cancer cells establish metabolic reprogramming with cancer-associated fibroblasts (CAFs) through lactate shuttle to enhance invasion, migration, and angiogenesis
Wang, X. T., Qu, Y., Ji, J., Liu, H., Luo, H., Li, J., & Han, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113470 · Cited by 30
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy
Belizário, J. E., Sangiuliano, B. A., Pérez-Sosa, M., Neyra, J. M., & Moreira, D. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00312 · Cited by 28
TTC22 promotes m6A-mediated WTAP expression and colon cancer metastasis in an RPL4 binding-dependent pattern
You, A., Tian, W., Yuan, H., Gu, L., Zhou, J., & Deng, D. (2022) · Oncogene · doi:10.1038/s41388-022-02402-x · Cited by 27
QSAR-derived affinity fingerprints (part 2): modeling performance for potency prediction
Cortés‐Ciriano, I., Škuta, C., Bender, A., & Svozil, D. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00444-5 · Cited by 28
Comprehensive Analyses of Ferroptosis-Related Alterations and Their Prognostic Significance in Glioblastoma
Tian, Y., Liu, H., Zhang, W., Liu, W., Wu, T., Yang, X., Zhao, J., & Sun, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.904098 · Cited by 28
PDGFR dimer-specific activation, trafficking and downstream signaling dynamics
Rogers, M. A., Campaña, M. B., Long, R., & Fantauzzo, K. A. (2022) · Journal of Cell Science · doi:10.1242/jcs.259686 · Cited by 29
Opportunities for pharmacoproteomics in biomarker discovery
Poulos, R. C., Cai, Z., Robinson, P. J., Reddel, R. R., & Zhong, Q. (2022) · PROTEOMICS · doi:10.1002/pmic.202200031 · Cited by 27
Multi-omics Characterization of Interaction-mediated Control of Human Protein Abundance levels
Sousa, A., Gonçalves, E., Mirauta, B. A., Ochoa, D., Stegle, O., & Beltrão, P. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001280 · Cited by 27
GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers
Hu, Q., Chen, J., Yang, W., Xu, M. L., Zhou, J., Tan, J., & Huang, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.990551 · Cited by 28
The Pursuit of Therapeutic Biomarkers with High-Throughput Cancer Cell Drug Screens
Williams, S. P., & McDermott, U. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.06.011 · Cited by 28
How to find the right drug for each patient? Advances and challenges in pharmacogenomics
Kalamara, A., Tobalina, L., & Sáez-Rodríguez, J. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.07.001 · Cited by 26
Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
Lin, Y.-H. T., Way, G. P., Barwick, B. G., Mariano, M. C., Marcoulis, M., Ferguson, I., Driessen, C., Boise, L., Greene, C. S., & Wiita, A. P. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000303 · Cited by 23
Loss of SNAI1 induces cellular plasticity in invasive triple-negative breast cancer cells
Tsirigoti, C., Ali, M. M., Maturi, V., Heldin, C., & Moustakas, A. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05280-z · Cited by 25
Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo
Ramovš, V., Secades, P., Song, J., Thijssen, B., Kreft, M., & Sonnenberg, A. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1146-8 · Cited by 25
Tissue specificity of in vitro drug sensitivity
Yao, F., Tonekaboni, S. A. M., Safikhani, Z., Smirnov, P., El-Hachem, N., Freeman, M., Manem, V. S., & Haibe‐Kains, B. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocx062 · Cited by 24
Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening
O’Duibhir, E., Carragher, N. O., & Pollard, S. M. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.11.001 · Cited by 22
Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus
Sánchez-Ibarra, H. E., Reyes, L. M., Jiang, X., Luna-Aguirre, C. M., Aguirre-Treviño, D., Morales-Alvarado, I. A., León-Cachón, R. B. R., Lavalle-Gonzalez, F. J., Morcos, F., & Barrera-Saldaña, H. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00320 · Cited by 24
FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits
Tsai, J. W., Cejas, P., Wang, D. K., Patel, S. K., Wu, D. W., Arounleut, P., Wei, X., Zhou, N., Syamala, S., Dubois, F. P. B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0671 · Cited by 25
Association of transcriptional levels of folate-mediated one-carbon metabolism-related genes in cancer cell lines with drug treatment response
Min, D.-J., Vural, S., & Krushkal, J. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.05.005 · Cited by 23
Encircling the regions of the pharmacogenomic landscape that determine drug response
Fernández‐Torras, A., Duran‐Frigola, M., & Aloy, P. (2019) · Genome Medicine · doi:10.1186/s13073-019-0626-x · Cited by 24
False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases
Kim, Y.-H., Song, Y., Kim, J.-K., Kim, T., Sim, H. W., Kim, H., Jang, H., Kim, Y., & Hong, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222535 · Cited by 24
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities
Stewart, C. A., Diao, L., Xi, Y., Wang, R., Ramkumar, K., Serrano, A. G., Tanimoto, A., Rodriguez, B. L., Morris, B. B., Shen, L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0361 · Cited by 23
Synthetic lethality in cancer drug discovery: challenges and opportunities
Gonçalves, E., Ryan, C. J., & Adams, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01273-7 · Cited by 27
Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays
Chen, M.-J. M., Li, J., Mills, G. B., & Liang, H. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00144 · Cited by 22
Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
Cruz-Duarte, R., de Almeida, C. R., Negrão, M., Fernandes, A., Borralho, P., Sobral, D., Gallego-Paez, L. M., Machado, D., Gramaça, J., Vílchez, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1992 · Cited by 22
From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures
Tseng, Y., & Boehm, J. S. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.007 · Cited by 21
Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma
Wu, L., Ge, Y., Yuan, Y., Li, H., Sun, H., Xu, C., Wang, Y., Zhao, T., Wang, X., Liu, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215864 · Cited by 21
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
Morris, J., Kunkel, M. W., White, S. L., Wishka, D. G., Lopez, O. D., Bowles, L., Brady, P. S., Ramsey, P., Grams, J., Rohrer, T. N., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0267 · Cited by 20
Genomic regression analysis of coordinated expression
Cai, L., Li, Q., Du, Y., Yun, J., Xie, Y., DeBerardinis, R. J., & Xiao, G. (2017) · Nature Communications · doi:10.1038/s41467-017-02181-0 · Cited by 21
Coordinated transcription of ANRIL and P16 genes is silenced by P16 DNA methylation
Gan, Y., Ma, W., Wang, X., Qiao, J., Zhang, B., Cui, C., Liu, Z., & Deng, D. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.01.10 · Cited by 21
Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology
Yu, J. X., Craig, A. J., Duffy, M. E., Villacorta-Martín, C., Miguela, V., de Galarreta, M. R., Scopton, A. P., Silber, L., Maldonado, A. Y., Rialdi, A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0571 · Cited by 21
Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis
Shahrouzi, P., Astobiza, I., Cortázar, A. R., Torrano, V., Macchia, A., Flores, J. M., Niespolo, C., Mendizabal, I., Caloto, R., Ercilla, A., et al. (2020) · Cancers · doi:10.3390/cancers12092593 · Cited by 21
Evaluating the consistency of large-scale pharmacogenomic studies
Rahman, R., Dhruba, S. R., Matlock, K., Niz, C. D., Ghosh, S., & Pal, R. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby046 · Cited by 18
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer
Wang, Y., Zhang, Y., Wang, F., Li, T., Song, X., Shi, H., Du, J., Zhang, H., Jing, H., Han, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21328-8 · Cited by 21
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
Uitdehaag, J. C. M., de Roos, J. A. D. M., Prinsen, M. B. W., Willemsen‐Seegers, N., de Vetter, J. R. F., Dylus, J., van Doornmalen, A. M., Kooijman, J. J., Sawa, M., van Gerwen, S. J. C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0403 · Cited by 19
Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency
Luo, C., Liang, J., Sharabi, K., Hatting, M., Perry, E. A., Tavares, C. D. J., Goyal, L., Srivastava, A., Bilodeau, M., Zhu, A. X., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0106 · Cited by 20
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Cai, J., Jacob, S., Kurupi, R., Dalton, K. M., Coon, C. M., Greninger, P., Egan, R. K., Stein, G. T., Murchie, E., McClanaghan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111095 · Cited by 19
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine
Kotelnikova, E. A., Pyatnitskiy, M. A., Paleeva, A. G., Kremenetskaya, O. S., & Vinogradov, D. V. (2016) · Oncotarget · doi:10.18632/oncotarget.9370 · Cited by 19
Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct Cell Types
Warchal, S. J., Dawson, J. C., & Carragher, N. O. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.730 · Cited by 19
USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma
Henrich, I. C., Young, R., Quick, L., Oliveira, A. M., & Chou, M. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0289 · Cited by 19
CeL-ID: cell line identification using RNA-seq data
Mohammad, T. A., Tsai, Y. S., Ameer, S., Chen, H.-I. H., Chiu, Y.-C., & Chen, Y. (2019) · BMC Genomics · doi:10.1186/s12864-018-5371-9 · Cited by 19
A landscape of synthetic viable interactions in cancer
Gu, Y., Wang, R., Han, Y., Zhou, W., Zhao, Z., Chen, T., Zhang, Y., Peng, F., Liang, H., Qi, L., et al. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw142 · Cited by 19
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Nguyen, L. V., & Caldas, C. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013189 · Cited by 19
Voltage-Gated Sodium Channels as Potential Biomarkers and Therapeutic Targets for Epithelial Ovarian Cancer
Brummelhuis, I. S. G., Fiascone, S. J., Hasselblatt, K. T., Frendl, G., & Elias, K. M. (2021) · Cancers · doi:10.3390/cancers13215437 · Cited by 18
Computational Drug Repurposing Based on a Recommendation System and Drug–Drug Functional Pathway Similarity
Shao, M., Jiang, L., Meng, Z., & Xu, J. (2022) · Molecules · doi:10.3390/molecules27041404 · Cited by 18
Safikhani et al. reply
Safikhani, Z., El-Hachem, N., Smirnov, P., Freeman, M., Goldenberg, A., Birkbak, N. J., Beck, A. H., Aerts, H. J. W. L., Quackenbush, J. F., & Haibe‐Kains, B. (2016) · Nature · doi:10.1038/nature19839 · Cited by 18
Prevalence, causes and impact of TP53-loss phenocopying events in human tumors
Fito-Lopez, B., Salvadores, M., Álvarez‐Álvarez, M. M., & Supek, F. (2023) · BMC Biology · doi:10.1186/s12915-023-01595-1 · Cited by 19
CREAMMIST: an integrative probabilistic database for cancer drug response prediction
Yingtaweesittikul, H., Wu, J., Mongia, A., Peres, R., Ko, K. K. K., Nagarajan, N., & Suphavilai, C. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac911 · Cited by 19
Increased TRIM31 gene expression is positively correlated with SARS-CoV-2 associated genes TMPRSS2 and TMPRSS4 in gastrointestinal cancers
Temena, M. A., & Acar, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-15911-2 · Cited by 17
Efficient algorithms to discover alterations with complementary functional association in cancer
Basso, R. S., Hochbaum, D. S., & Vandin, F. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006802 · Cited by 16
Computational Methods for the Integrative Analysis of Genomics and Pharmacological Data
Caroli, J., Dori, M., & Bicciato, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00185 · Cited by 16
Expression and prognostic analyses of SCAMPs in pancreatic adenocarcinoma
Mao, F., Duan, H., Allamyradov, A., Xin, Z., Du, Y., Wang, X., Xu, P., Li, Z., Qian, J., & Yao, J. J. (2021) · Aging · doi:10.18632/aging.202377 · Cited by 16
MYC dosage compensation is mediated by miRNA-transcription factor interactions in aneuploid cancer
Acón, M., Geiß, C., Torres-Calvo, J., Bravo‐Estupiñan, D. M., Oviedo, G., Arias-Arias, J. L., Rojas-Matey, L. A., Baéz, E., Vásquez-Vargas, G., Oses-Vargas, Y., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103407 · Cited by 16
Predictive and therapeutic implications of a novel PLCγ1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer
Cruz-Duarte, R., de Almeida, C. R., Negrão, M., Fernandes, A., Borralho, P., Sobral, D., Gallego-Paez, L. M., Machado, D., Gramaça, J., Vı́lchez, J. M., et al. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 16
Bioinformatics Approaches to Predict Drug Responses from Genomic Sequencing
Madhukar, N. S., & Elemento, O. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7493-1_14 · Cited by 15
Understanding of researcher behavior is required to improve data reliability
Wass, M. N., Ray, L., & Michaelis, M. (2019) · GigaScience · doi:10.1093/gigascience/giz017 · Cited by 19
Novel GSH-responsive prodrugs derived from indole-chalcone and camptothecin trigger apoptosis and autophagy in colon cancer
Wang, H., Nie, C., Luo, M., Bai, Q., Yao, Z., Lv, H., Chen, B., Wang, J., Xu, W., Wang, S., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107056 · Cited by 15
Methodological challenges in translational drug response modeling in cancer: A systematic analysis with FORESEE
Schätzle, L.-K., Esfahani, A. H., & Schuppert, A. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007803 · Cited by 16
Requirement for LIM kinases in acute myeloid leukemia
Jensen, P., Carlet, M., Schlenk, R. F., Weber, A., Kress, J., Brunner, I., Slabicki, M. M., Grill, G., Weisemann, S., Cheng, Y., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0943-5 · Cited by 16
Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines
Koras, K., Kizling, E., Juraeva, D., Staub, E., & Szczurek, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-94564-z · Cited by 16
[18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response
Zhang, H., Abou, D. S., Lu, P., Hasson, A. M., Villmer, A., Benabdallah, N., Jiang, W., Ulmert, D., Carlin, S., Rogers, B. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-17460-0 · Cited by 15
Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small cell lung cancer
Lastwika, K. J., Kunihiro, A. G., Solan, J. L., Zhang, Y., Taverne, L. R., Shelley, D., Rho, J.-H., Randolph, T. W., Li, C. I., Grogan, E. L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add8469 · Cited by 15

Authors: The Cancer Cell Line Encyclopedia Consortium, & The Genomics of Drug Sensitivity in Cancer Consortium
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2015-11-16
Volume: 528
Issue: 7580
Pages: 84-87
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature15736
PMC: PMC6343827
OpenAlex: W2318806991
Cited by: 418
References: 10
Citations by year: 2026: 17 · 2025: 26 · 2024: 33 · 2023: 37 · 2022: 49 · 2021: 47 · 2020: 38 · 2019: 78 · 2018: 36 · 2017: 37 · 2016: 19
FWCI: 31.30
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: Wellcome Trust (086357, 102696STRATTON, 102696)
Cancer Research UK (A16629)
National Institutes of Health (5u54hg006097-03)
National Human Genome Research Institute (1U54HG006097-01, U54-HG006097)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: cancer cell lines, drug sensitivity, pharmacogenomics, GDSC, data concordance, anticancer drug response, drug library
MeSH terms: Humans, Neoplasms, Pharmacogenetics, Reproducibility of Results, Databases, Factual, Inhibitory Concentration 50, Cell Line, Tumor, Datasets as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacogenomic agreement between two cancer cell line data sets

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks